| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/07/2002 | US20020028212 Recombinant viruses coding for a glutamate decarboxylase (gad) activity |
| 03/07/2002 | US20020028205 May be comprised of a heavily glycosylated mucin part, which mediates binding to selectins, such as PSGL-1; absorber to prevent a hyperacute rejection of a xenotransplant |
| 03/07/2002 | US20020028201 Element A, which is a plastic with a group derived from a carboxy acid (e.g., an acrylate polymer), is hydrogen bonded to an element B (e.g., polyalkylene glycol; coupling physiologically and/or pharmacologically active substances |
| 03/07/2002 | US20020028196 Administration of an effective amount of D-Ribose to a mammal that would benefit enhancement of the immune response. |
| 03/07/2002 | US20020028195 Viruses for the treatment of cellular proliferative disorders |
| 03/07/2002 | US20020028190 Compositions of non-ionic block copolymers to treat autoimmune, proliferative, and inflammatory diseases and methods of use thereof |
| 03/07/2002 | US20020028183 Medicaments |
| 03/07/2002 | US20020028181 Polyacid/polyalkylene oxide foams and gels and methods for their delivery |
| 03/07/2002 | DE10055706A1 Cosmetic or dermatological topical formulation, useful for the protection of skin cells from physical, chemical or biological effects, contains a di-sugar alcohol phosphate of 3-6C sugar alcohols |
| 03/07/2002 | DE10042093A1 Antikonvulsiv wirkende 6,7-Dihydro-pyrrolo[3,4-d]pyridin-5-one und Verfahren zu deren Darstellung Anticonvulsant acting 6,7-dihydro-pyrrolo [3,4-d] pyridin-5-one and processes for their representation |
| 03/07/2002 | DE10042092A1 Antikonvulsiv wirkende 2,5-Dihydro-pyrazolo(3,4-d)pyrimidin-4-one und Verfahren zu deren Darstellung Anticonvulsant acting 2,5-dihydro-pyrazolo (3,4-d) pyrimidin-4-one and processes for their representation |
| 03/07/2002 | DE10042064A1 Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Quinazolines, medicaments containing these compounds, their use and process for their preparation |
| 03/07/2002 | DE10042062A1 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung Bicyclic heterocycles, pharmaceutical compositions containing them, their use and process for their Hertel Lung |
| 03/07/2002 | DE10042061A1 Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Bicyclic heterocycles, pharmaceutical compositions containing them, their use and process for their preparation |
| 03/07/2002 | DE10042060A1 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Bicyclic heterocycles, pharmaceutical compositions containing them, their use and process for their preparation |
| 03/07/2002 | DE10042059A1 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Bicyclic heterocycles, pharmaceutical compositions containing them, their use and process for their preparation |
| 03/07/2002 | DE10042058A1 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Bicyclic heterocycles, pharmaceutical compositions containing them, their use and process for their preparation |
| 03/07/2002 | DE10041574A1 Chromenonderivate Chromenonderivate |
| 03/07/2002 | DE10041428A1 Biphenylderivate Biphenyl |
| 03/07/2002 | DE10041423A1 Biphenylderivate Biphenyl |
| 03/07/2002 | DE10040933A1 Verwendung von beta-Mannosylglycerat (Firoin) und/oder Derivaten, insbesondere dem beta-Mannosylglyceramid (Firoin-A), in kosmetischen und dermatologischen Formulierungen Use of beta-mannosylglycerate (firoin) and / or derivatives, in particular the beta-mannosylglyceramide (firoin-A), in cosmetic and dermatological formulations |
| 03/07/2002 | DE10040932A1 Cosmetic or dermatological topical formulation, useful for the protection of skin cells from physical, chemical or biological effects, contains a di-sugar alcohol phosphate of 3-6C sugar alcohols |
| 03/07/2002 | DE10040931A1 Verwendung von cyclischem 2,4 Diphosphoglycerat (cDGP) und/oder Derivaten in kosmetischen und dermatologischen Formulierungen The use of cyclic 2,4 diphosphoglycerate (CDGP) and / or derivatives in cosmetic and dermatological formulations |
| 03/07/2002 | DE10040783A1 AZA-Aminosäurederivate (Faktor X¶a¶-Inhibitoren 15) AZA-amino acid derivatives (factor inhibitors X¶a¶ 15) |
| 03/07/2002 | DE10040742A1 Ubiquitin-proteasome system regulating composition containing proteasome inhibitor, e.g. MG132, is useful for cardiovascular protection, e.g. in preventing or treating restenosis or cardiac hypertrophy |
| 03/07/2002 | DE10040052A1 Verwendung von Protonenpumpen-Hemmern zur Behandlung von Entzündungen, insbesondere von Erkrankungen des Bewegungsapparates Use of proton pump inhibitors for the treatment of inflammation, especially of disorders of the musculoskeletal system |
| 03/07/2002 | DE10038043A1 Phamakologisch wirksame Substanz zur Behandlung kardiovaskulärer Erkrankungen Of pharmacologically active substance for the treatment of cardiovascular diseases |
| 03/07/2002 | DE10035928A1 Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel New heteroaryl derivatives and their use as medicaments |
| 03/07/2002 | DE10035927A1 Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel New heteroaryl derivatives and their use as medicaments |
| 03/07/2002 | DE10035908A1 Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel New heteroaryl derivatives and their use as medicaments |
| 03/07/2002 | DE10033880A1 Enhancing intracellular levels of a cyclic nucleotide, useful to treat e.g. chemotherapy resistance, comprises administering inhibitors of multidrug resistance protein 5 and phosphodiesterase |
| 03/07/2002 | CA2746787A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | CA2731273A1 Processes and intermediates for preparing retroviral protease inhibitors |
| 03/07/2002 | CA2697205A1 Peptidomimetic protease inhibitors |
| 03/07/2002 | CA2497686A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | CA2425367A1 Oct formulations |
| 03/07/2002 | CA2424146A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
| 03/07/2002 | CA2424026A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria |
| 03/07/2002 | CA2424011A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain |
| 03/07/2002 | CA2421893A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | CA2421524A1 Materials and methods for the treatment or prevention of obesity |
| 03/07/2002 | CA2421507A1 Screen for glutamate reuptake inhibitors, stimulators, and modulators |
| 03/07/2002 | CA2421106A1 Manzamines for treatment of drug resistant infection |
| 03/07/2002 | CA2420987A1 Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine |
| 03/07/2002 | CA2420969A1 Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors |
| 03/07/2002 | CA2420935A1 N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide |
| 03/07/2002 | CA2420906A1 Use of a composition comprising an extract of pollen for the treatment of edema |
| 03/07/2002 | CA2420871A1 Cephalosporin antibiotics and prodrugs thereof |
| 03/07/2002 | CA2420869A1 Compounds having activity as inhibitors of cytochrome p450rai |
| 03/07/2002 | CA2420867A1 Methods for enhancing the efficacy of cancer therapy |
| 03/07/2002 | CA2420852A1 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction |
| 03/07/2002 | CA2420846A1 Treatment of urinary dysfunction |
| 03/07/2002 | CA2420840A1 Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3' |
| 03/07/2002 | CA2420835A1 Composition and method for treatment of hypertriglyceridemia |
| 03/07/2002 | CA2420823A1 Use of a composition comprising an extract of pollen for the treatment of irritability |
| 03/07/2002 | CA2420804A1 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors |
| 03/07/2002 | CA2420765A1 Anti-angiogenic peptides |
| 03/07/2002 | CA2420673A1 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
| 03/07/2002 | CA2420569A1 Use of threo-methylphenidate compounds to enhance memory |
| 03/07/2002 | CA2420535A1 Sustained release formulations for growth hormone secretagogues |
| 03/07/2002 | CA2420532A1 Pharmaceutical formulation of salmeterol and fluticasone propionate |
| 03/07/2002 | CA2420518A1 Clear antiperspirants and deodorants made with siloxane-based polyamides |
| 03/07/2002 | CA2420363A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | CA2420288A1 2,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonvulsive action and methods for producing the same |
| 03/07/2002 | CA2420286A1 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| 03/07/2002 | CA2420178A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
| 03/07/2002 | CA2420122A1 7-oxo pyridopyrimidines |
| 03/07/2002 | CA2420103A1 Modulation of fas and fasl expression |
| 03/07/2002 | CA2419841A1 Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
| 03/07/2002 | CA2419699A1 Gem-substituted .alpha. v .beta. 3 integrin antagonists |
| 03/07/2002 | CA2419623A1 Method for treatment of migraine using pde5 inhibitors |
| 03/07/2002 | CA2419616A1 Novel ester or amide derivatives |
| 03/07/2002 | CA2419567A1 Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
| 03/07/2002 | CA2419480A1 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| 03/07/2002 | CA2419472A1 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | CA2419399A1 Nucleoside derivatives for the treatment of hepatitis c |
| 03/07/2002 | CA2419256A1 Use of an aldosterone receptor antagonist to improve cognitive function |
| 03/07/2002 | CA2419255A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| 03/07/2002 | CA2419251A1 Nucleic acid constructs including a novel t-cell active promoter, and pharmaceutical compositions and methods utilizing same for regulating t-cell mediated immune response |
| 03/07/2002 | CA2419249A1 Water-dispersible encapsulated sterols |
| 03/07/2002 | CA2419152A1 Methods of using agents that modulate bone formation and inhibit adipogenesis |
| 03/07/2002 | CA2418038A1 Paroxetine compositions and processes for making the same |
| 03/07/2002 | CA2417042A1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 03/07/2002 | CA2386552A1 Method for synthesizing flosequinan from 4-fluoroanthranilic acid |
| 03/07/2002 | CA2382687A1 A therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives |
| 03/06/2002 | EP1184465A2 Method for diagnosing polymorphisms in human MCT-1 and drugs related to such polymorphisms |
| 03/06/2002 | EP1184388A1 Sulphostin analogues and processes for the preparation of sulphostin and analogues thereof |
| 03/06/2002 | EP1184385A1 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
| 03/06/2002 | EP1184384A1 1-(Alkyl), 1-((heteroaryl)alkyl) and 1-((aryl)alkyl)-7-pyridin-4-ylimidazo(1,2a)pyrimidin-5(1H)-one derivatives |
| 03/06/2002 | EP1184373A1 Tricyclic compounds |
| 03/06/2002 | EP1184372A1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) |
| 03/06/2002 | EP1184370A2 Compounds with growth hormone releasing properties |
| 03/06/2002 | EP1184367A1 Amide derivatives |
| 03/06/2002 | EP1184366A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha(ppar) |
| 03/06/2002 | EP1184362A1 Phenol derivatives, process for preparation of the same and use thereof |
| 03/06/2002 | EP1184037A1 Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance |
| 03/06/2002 | EP1184036A2 Heterocyclic compounds, their production and use as tachykinin receptor antagonists |
| 03/06/2002 | EP1184035A2 Use of growth hormone secretagogues for treatment of physical performance decline |
| 03/06/2002 | EP1184034A2 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 03/06/2002 | EP1184030A1 Antibacterial composition comprising trimethylnorbornanylcyclohexanol derivatives |